cagrilintide trial In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and Comparative Effectiveness of CagriSegma, Semaglutide,
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network MetaAnalysis of Randomized Clinical Trials Hamarsheh 2026 Endocrinology, Diabetes & Metabolism Wiley Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase Cagrilintide vs Retatrutide Compared Dosage Peptide
Pay in 4 interest-free payments of $5.69 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


